Login | Users Online: 1005  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us
Year : 2020  |  Volume : 21  |  Issue : 1  |  Page : 32-36

Anticoagulation in patients with atrial fibrillation and coronary artery disease

Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar

Correspondence Address:
Dr. Fahad Abdullah Alkindi
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and Permissions

The management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary artery disease remains a challenge in clinical practice. This group of patients has indications for both oral anticoagulation and antiplatelet therapy. Such combination will require careful considerations of both thromboembolic and bleeding risks. There have been several big trials looking at the rationale of treating those patients with an oral anticoagulant in combination with one (dual-therapy strategy) or two antiplatelet agents (triple-therapy strategy).

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded159    
    Comments [Add]    
    Cited by others 4    

Recommend this journal